Disparities in Emergency Department Naloxone and Buprenorphine Initiation.


Journal

The western journal of emergency medicine
ISSN: 1936-9018
Titre abrégé: West J Emerg Med
Pays: United States
ID NLM: 101476450

Informations de publication

Date de publication:
30 Jun 2023
Historique:
received: 27 08 2022
accepted: 08 02 2023
medline: 3 8 2023
pubmed: 1 8 2023
entrez: 1 8 2023
Statut: epublish

Résumé

Prescribing of buprenorphine and naloxone in the emergency department (ED) has been shown to be an effective intervention. The purpose of this study was to determine the frequency of prescribing of naloxone and buprenorphine and the sub-groups that may be more or less likely to receive treatment. We used a national electronic health record database to identify patients with opioid poisoning or overdose presenting between January 2019-December 2021. Patients who were prescribed naloxone or buprenorphine were identified in this dataset and then further segmented based on self-identified gender, age, racial and ethnic identity, income categories, and social vulnerability index in order to identify sub-groups that may be less likely to be prescribed treatment. We found 74,004 patients in the database whom we identified as presenting to the ED with an opioid poisoning or overdose. Overall, 22.8% were discharged with a prescription for naloxone, while 0.9% of patients were discharged with buprenorphine products. Patients were less likely to receive naloxone prescriptions if they were female, White or Pacific Islander, non-Hispanic, not between the ages of 18-65, and non-English speaking. We found the same pattern for buprenorphine prescriptions except that the results were not significant for ethnicity and English-speaking. Despite evidence supporting its use, buprenorphine is not prescribed from the ED in a substantial proportion of patients. Naloxone is prescribed to a higher percentage, although still a minority of patients receive it. Some sub-groups are disadvantaged in the prescribing of these products. Further study may assist in improving the prescribing of these therapies.

Identifiants

pubmed: 37527392
pii: westjem.58636
doi: 10.5811/westjem.58636
pmc: PMC10393464
doi:

Substances chimiques

Naloxone 36B82AMQ7N
Buprenorphine 40D3SCR4GZ
Analgesics, Opioid 0
Buprenorphine, Naloxone Drug Combination 0
Narcotic Antagonists 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

710-716

Références

Drug Alcohol Depend. 2021 Sep 1;226:108849
pubmed: 34198132
Drug Alcohol Depend. 2019 Apr 1;197:78-82
pubmed: 30784952
Mol Psychiatry. 2019 Dec;24(12):1868-1883
pubmed: 29934549
Cochrane Database Syst Rev. 2004;(3):CD002207
pubmed: 15266465
J Subst Abuse Treat. 2021 Nov;130:108405
pubmed: 34118697
Ann Emerg Med. 2022 Mar;79(3):225-236
pubmed: 34802772
Am J Emerg Med. 2022 May;55:98-102
pubmed: 35304308
J Subst Abuse Treat. 2021 Dec;131:108588
pubmed: 34384652
J Subst Abuse Treat. 2022 Jan;132:108648
pubmed: 34742607
J Gen Intern Med. 2017 Jun;32(6):660-666
pubmed: 28194688
Ann Emerg Med. 2021 Dec;78(6):759-772
pubmed: 34353655
Drug Alcohol Depend. 2021 May 1;222:108673
pubmed: 33773868
J Addict Dis. 2022 Oct-Dec;40(4):518-526
pubmed: 35238283
JAMA Netw Open. 2021 Jul 1;4(7):e2117128
pubmed: 34264326
J Racial Ethn Health Disparities. 2022 Apr;9(2):722-730
pubmed: 33977509
Harm Reduct J. 2020 May 13;17(1):31
pubmed: 32404109
Am J Emerg Med. 2022 Jan;51:114-118
pubmed: 34735968
Subst Abuse Treat Prev Policy. 2022 May 25;17(1):41
pubmed: 35614487
MMWR Morb Mortal Wkly Rep. 2021 May 07;70(18):661-666
pubmed: 33956783
BMC Public Health. 2014 Apr 01;14:297
pubmed: 24684801
Ann Intern Med. 2018 Aug 7;169(3):137-145
pubmed: 29913516
J Subst Abuse Treat. 2011 Jun;40(4):349-56
pubmed: 21310583
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1740-1746
pubmed: 34914673
J Subst Abuse Treat. 2022 Aug;139:108785
pubmed: 35537918
Drug Alcohol Depend. 2018 Sep 1;190:170-178
pubmed: 30041092
Prev Chronic Dis. 2008 Jul;5(3):A96
pubmed: 18558046
MMWR Morb Mortal Wkly Rep. 2021 Apr 16;70(15):541-546
pubmed: 33857070
Addict Behav. 2022 Jan;124:107113
pubmed: 34543869
BMJ. 2013 Jan 30;346:f174
pubmed: 23372174

Auteurs

Joan Papp (J)

MetroHealth Campus of Case Western Reserve University, Department of Emergency Medicine, Cleveland, Ohio.

Charles Emerman (C)

MetroHealth Campus of Case Western Reserve University, Department of Emergency Medicine, Cleveland, Ohio.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH